http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108373491-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-19 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-19 |
| filingDate | 2018-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108373491-B |
| titleOfInvention | Preparation method of nelarabine |
| abstract | The invention discloses a preparation method of nelarabine, which takes cyclocytidine hydrochloride and 2-amino-6-chloropurine as raw materials, the cyclocytidine hydrochloride is hydrolyzed and then acetyl is used for protecting amino and hydroxyl to form tetraacetyl cytarabine, and then the tetraacetyl cytarabine and silanized 2-amino-6-methoxypurine are subjected to base conversion reaction under the action of Lewis acid trimethylsilyl trifluoromethanesulfonate to obtain a target product of nelarabine. The raw materials adopted by the invention are cheap and easy to purchase, the reaction route is short, the conditions are mild, the equipment requirement is low, the production cost is low, the reaction is safe and easy to control, and the possibility of reducing the production and manufacturing cost of the nelarabine is provided. |
| priorityDate | 2018-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 100.